Investigational drug · Phase 2
OM-85
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent Wheezing, Wheezing Lower Respiratory Illness.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
14
Any phase or sponsor naming "OM-85"
First trial start
2023
Jun 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OM-85", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent Wheezing
- Wheezing Lower Respiratory Illness
Largest trials
Live from ClinicalTrials.gov: studies naming "OM-85" as an intervention, largest first.
- PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyPivotal-lookingCompleted
University of North Carolina, Chapel HillAcademic, hospital or other
NCT04129931 · 950 participants · Start Dec 19, 2019 · Primary completion Feb 19, 2025
Drug: MCT; Clazakizumab and 3 more · For: Asthma
Sites: Scottsdale, Arizona; Tucson, Arizona; Sacramento, California · 29 sites in all
- Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract IllnessPivotal-lookingCompleted
University of ArizonaAcademic, hospital or other
NCT02148796 · 822 participants · Start Jan 1, 2017 · Primary completion Jan 30, 2026
Drug: Broncho-Vaxom (BV) · For: Asthma; Wheezing
Sites: Phoenix, Arizona; Tucson, Arizona; Oakland, California · 11 sites in all
- OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory IllnessPivotal-lookingCompleted
OM Pharma SAIndustry
NCT05677763 · 525 participants · Start Dec 12, 2022 · Primary completion Mar 10, 2026
Drug: OM-85; Placebo · For: Respiratory Tract Infections; Wheezing Lower Respiratory Illness
Sites: München, Germany; Schönau am Königssee, Germany; Hanover, Germany · 42 sites in all
- Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.Pivotal-lookingRecruiting
Franciscus GasthuisAcademic, hospital or other
NCT05063149 · 500 participants (planned) · Start Mar 18, 2022 · Primary completion Dec 2029
Drug: Broncho-Vaxom · For: Wheezing; LRTI; Premature
Sites: Rotterdam, Netherlands
- OM 85 to Prevent Respiratory Infections in Older At Risk PatientsPivotal-lookingRecruiting
Campus Bio-Medico UniversityAcademic, hospital or other
NCT06655272 · 360 participants (planned) · Start Feb 1, 2025 · Primary completion Jan 2026
Drug: Bacterial Lysate; Placebo · For: Respiratory Tract Infections (RTI)
Sites: Roma, Italy
- OM 85 to Prevent Respiratory Infections in Older At Risk PatientsPivotal-lookingActive, not recruiting
Fondazione Policlinico Universitario Campus Bio-MedicoAcademic, hospital or other
NCT07178002 · 360 participants (planned) · Start Dec 19, 2024 · Primary completion Jan 2026
Drug: Bacterial Lysate; Placebo · For: Respiratory Tract Infections (RTI)
Sites: Roma, Italy
- A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent WheezingPivotal-lookingCompleted
OM Pharma SAIndustry
NCT05857930 · 296 participants · Start Jun 20, 2023 · Primary completion Sep 15, 2026
Drug: OM-85; Placebo · For: Recurrent Wheezing; Wheezing Lower Respiratory Illness
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 38 sites in all
- Prevention of OM-85 on Bronchiectasis ExacerbationPivotal-lookingCompleted
Chinese Academy of Medical SciencesAcademic, hospital or other
NCT01968421 · 196 participants · Start Mar 1, 2015 · Primary completion Nov 23, 2018
Drug: OM-85 BV · For: Bronchiectasis With Acute Exacerbation
Sites: Beijing, China; Shanghai, China
- Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic DermatitisPivotal-lookingCompleted
Vifor PharmaIndustry
NCT03047954 · 179 participants · Start Jul 2003 · Primary completion Dec 2006
Drug: Broncho-Vaxom; Placebo - Cap · For: Atopic Dermatitis
Kecioren Education and Training HospitalAcademic, hospital or other
NCT00733226 · 80 participants · Start Aug 2007 · Primary completion Sep 2008
Drug: OM-85 BV (Broncho-Vaxom); OM-85 BV (placebo) · For: Asthma
Sites: Ankara, Turkey (Türkiye) · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Evaluating the therapeutic benefit of bacterial lysates in chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Almujadib A, Alotaibi R, Alsultan A, et al. · Front Med (Lausanne) 2026
- Preclinical Evaluation of Bacterial Lysates in Murine Disease Models: A Systematic Review.
Ancuța DL, Coman C · Immun Inflamm Dis 2026
- Bacterial Lysates Add-On Therapy to Reduce Postoperative Recurrence in Nasal Polyps.
Deng H, Qiu H, Yuan T, et al. · Laryngoscope 2026
- Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial.
Morgan WJ, Mauger DT, Bacharier LB, et al. · Lancet 2026
- Assessing the Reduction of Recurrent Admissions Using OM-85 for the Treatment of Preschool Wheeze (ARROW): Protocol for a Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial.
Costa-Pinto JC, van Arragon M, Lee KJ, et al. · J Paediatr Child Health 2026
- Impact of oral bacterial lysates on asthma control and immune parameters in children: evidence from an updated systematic review and meta-analysis of randomized trials.
Chen Y, Shi L, Wang Y, et al. · Front Pharmacol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.